Penpulimab Combined With Anlotinib in Neoadjuvant Treatment of Resectable Non-small Cell Lung Cancer

NCT05387109 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

41

Enrollment

OTHER

Sponsor class

Conditions

NSCLC

Interventions

DRUG: penpulimab combined with anlotinib

Sponsor

Tang-Du Hospital